Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

Abstract Background Soft tissue sarcoma (STS) comprises a family of rare, heterogeneous tumors of mesenchymal origin. Single-agent doxorubicin remains the first-line standard-of-care treatment for advanced and inoperable STS, but response rates are only around 15%. In 2016, phase Ib/II clinical tria...

Full description

Bibliographic Details
Main Authors: Jasmien Cornillie, Agnieszka Wozniak, Britt Van Renterghem, Nathalie Van Winkel, Jasmien Wellens, Yemarshet K. Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Cancer
Subjects:
Olaratumab
Platelet-derived growth factor receptor alpha (PDGFRA)
Soft tissue sarcoma
Patient-derived xenograft
Online Access:http://link.springer.com/article/10.1186/s12885-019-5872-1

Internet

http://link.springer.com/article/10.1186/s12885-019-5872-1

Similar Items